Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06238778 · ClinicalTrials.gov registry record · Phase 2
Phase 2b Trial Comparing HDV-Insulin Lispro to Insulin Lispro in Adults With Type 1 Diabetes Receiving Insulin Degludec
A Phase 2 study of Diabetes Mellitus, Type 1, sponsored by Diasome Pharmaceuticlas.
- Active
- Registry status
- Phase 2
- Development phase
- 227
- Enrollment target
- 20
- Study locations
NCT06238778 is a Phase 2 study of Diabetes Mellitus, Type 1 that is active but no longer recruiting, run by Diasome Pharmaceuticlas. The registered enrollment target is 227 participants, below the 1,264-participant average among 118 other Diabetes Mellitus, Type 1 trials with a reported enrollment target (82% lower). The trial reports 20 study locations across 10 states.
The verdict
NCT06238778, a Phase 2 study of Diabetes Mellitus, Type 1, is active but no longer recruiting, sponsored by Diasome Pharmaceuticlas.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 227 participants
- Enrollment target
- 20
- Study locations
Study Summary
The goal of this study is to see if directing insulin to the liver will improve the low blood sugar that sometimes happens when injecting insulin in Type 1 diabetes patients. Participants will use continuous glucose monitoring to measure the sugar levels in their blood, and work with the doctor to find the best doses. One group of patients will get the liver targeting insulin, and the other group will use insulin they normally use for treating Type 1 diabetes. The participant will be part of the study for up to 32 weeks.
Conditions Studied
Interventions
- DRUG HDV-Lispro
- DRUG Lispro
Study Locations (20)
Georgia
- Atlanta Diabetes Associates - Atlanta
- East Coast Institute for Research - Canton
- Physicians Research Associates, LLC - Lawrenceville
- Endocrine Research Solutions, Inc. - Roswell
California
- Marvel Clinical Research - Huntington Beach
- Pasadena Clinical Trials - Pasadena
- Diabetes Research Center - Tustin
Florida
- East Coast Institute for Research - Jacksonville
- University of Miami Diabetes Research Institute - Miami
- Metabolic Research Institute - West Palm Beach
North Carolina
- Asheville Clinical Research - Asheville
- UNC EnDO Clinical Research Unit - Chapel Hill
- Physician's East - Greenville
Illinois
- University of Chicago Kovler Diabetes Center - Chicago
- Endeavor Health - Skokie
Colorado
- University of Colorado, Barbara Davis Center - Denver
Indiana
- Indiana Medical Research Institute - Merrillville
New York
- SUNY Upstate Medical University - Syracuse
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 227 participants |
| Start Date | 2024-01-23 |
| Est. Completion | 2025-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06238778
The ClinicalTrials.gov registry entry for NCT06238778 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 227 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,264-participant average among 118 other Diabetes Mellitus, Type 1 trials with a reported enrollment target (82% lower). The listed sponsor is Diasome Pharmaceuticlas, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Diabetes Mellitus, Type 1 appearing as the primary indexed condition, and to 2 interventions - of which HDV-Lispro is the first listed.
NCT06238778 reports 20 study locations spanning 10 distinct geographic areas - top geographies include Georgia, California, Florida.
Frequently Asked Questions
What is clinical trial NCT06238778 about?
NCT06238778 is a clinical study titled "Phase 2b Trial Comparing HDV-Insulin Lispro to Insulin Lispro in Adults With Type 1 Diabetes Receiving Insulin Degludec". The goal of this study is to see if directing insulin to the liver will improve the low blood sugar that sometimes happens when injecting insulin in Type 1 diabetes patients. Participants will use continuous glucose monitoring to measure the sugar levels in their blood, and work with the doctor to f...
What is the current status of trial NCT06238778?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 227 participants. The study started on 2024-01-23. Estimated completion is 2025-12.
What conditions does trial NCT06238778 study?
This clinical trial studies the following conditions: Diabetes Mellitus, Type 1.
What interventions are being tested in trial NCT06238778?
The interventions under investigation include: HDV-Lispro (DRUG), Lispro (DRUG).
Who is sponsoring clinical trial NCT06238778?
This trial is sponsored by Diasome Pharmaceuticlas, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06238778 being conducted?
This trial has 20 study locations across California, Colorado, Florida, Georgia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diabetes Mellitus, Type 1
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Islet Transplantation in Type 1 Diabetic Kidney Allograft
RECRUITING · Phase 2
-
Repeat BCG Vaccinations For The Treatment Of Pediatric Type 1 Diabetes
RECRUITING · Phase 2
-
Diabetes Autoimmunity Withdrawn In New Onset and In Established Patients
ACTIVE NOT RECRUITING · Phase 2
-
Janus Kinase (JAK) Inhibitors to Preserve C-Peptide Production in New Onset Type 1 Diabetes (T1D)
ACTIVE NOT RECRUITING · Phase 2
-
Comparison of Hepatic Directed Vesicle (HDV)-Insulin Lispro Versus Insulin Lispro to Further Improve Glycemic Control
COMPLETED · Phase 2
-
To Examine the Lung When People With Diabetes Take an Inhaled Form of Insulin, Compared to Subcutaneous Insulin.
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.